Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • COMMENT

Strategic recommendations from the STARS project to foster academic drug development

Improved understanding of regulatory requirements by academic researchers can accelerate the translation of new medical interventions to the clinic. Here, we highlight the recommendations of the ‘Strengthening Training of Academia in Regulatory Science’ (STARS) project to improve the interaction and knowledge exchange between academics and regulators, and thereby advance academic drug development.
  1. Viktoriia Starokozhko

    1. Dutch Medicines Evaluation Board (MEB), Utrecht, The Netherlands; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Anne Heß

    1. Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  3. Wiebke Löbker

    1. Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  4. Wolfgang Ballensiefen

    1. German Aerospace Center (DLR), Project Management Agency, Health, Innovation for Disease Related Research and Personalised Medicine, Bonn, Germany.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  5. Eleonora Agricola

    1. Italian Medicines Agency (AIFA), Rome, Italy.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  6. Bettina Ziegele

    1. Paul Ehrlich Institute (PEI), Federal Institute for Vaccines and Biomedicines, Langen, Germany.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  7. Marko J. Kallio

    1. Finnish Medicines Agency (FIMEA), Helsinki, Finland.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  8. Laurence O’Dwyer

    1. Health Products Regulatory Authority (HPRA), Dublin, Ireland.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  9. Yoana Nuevo

    1. Spanish Agency of Medicines and Medical Devices (AEMPS), Madrid, Spain.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  10. Peter G. M. Mol

    1. Dutch Medicines Evaluation Board (MEB), Utrecht, The Netherlands; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; European Medicines Agency (EMA), Amsterdam, The Netherlands.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  11. Anna M. G. Pasmooij

    1. Dutch Medicines Evaluation Board (MEB), Utrecht, The Netherlands.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Academia plays a key role in drug discovery and development, especially for innovative medicines and technologies1,2. However, progressing projects into clinical development is often challenging for academic drug researchers3, in part owing to a lack of knowledge regarding regulatory requirements and skills for navigating the regulatory system4.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 22, 251-252 (2023)

doi: https://doi.org/10.1038/d41573-023-00021-z

Acknowledgements

The STARS project was funded by Horizon 2020 (grant number 825881). We would like to acknowledge the support that we received from other STARS members while preparing the STARS Common Strategy, including the recommendations.

References

  1. de Wilde, S., Guchelaar, H.J., Zandvliet, M.L. & Meij., P. Clinical development of gene- and cell-based therapies: overview of the European landscape. Mol. Ther. Methods Clin. Dev. 3, 16073 (2016).

    Article  PubMed  Google Scholar 

  2. Kinch, M.S., Horn, C., Kraft, Z. & Schwartz, T. Rising academic contributions to drug development: evidence of vigor or trauma? ACS Pharmacol. Transl. Sci. 3, 1427−1429 (2020).

    Article  PubMed  Google Scholar 

  3. Gilliland, C. T., et al. Putting translational science on to a global stage. Nat. Rev. Drug Discov. 15, 217–218 (2016).

    Article  PubMed  Google Scholar 

  4. Starokozhko, V. et al. STARS consortium. Strengthening regulatory science in academia: STARS, an EU initiative to bridge the translational gap. Drug Discov. Today 26, 283–288 (2021).

    Article  PubMed  Google Scholar 

  5. Kallio, M. J. et al. Translating academic drug discovery into clinical development: a survey of the awareness of regulatory support and requirements among stakeholders in Europe. Clin. Pharmacol. Ther. 113, 349–359 (2023).

    Article  PubMed  Google Scholar 

Download references

Supplementary Information

  1. Supplementary information

Competing Interests

The authors declare no competing interests.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links